Australia markets closed

Teva Pharmaceutical Industries Limited (TEVJF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
10.26-0.41 (-3.84%)
At close: 12:22PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close10.67
Open10.06
BidN/A x N/A
AskN/A x N/A
Day's range10.06 - 10.26
52-week range6.92 - 13.88
Volume616
Avg. volume344
Market cap11.264B
Beta (5Y monthly)1.47
PE ratio (TTM)N/A
EPS (TTM)-3.63
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Nov 2017
1y target estN/A
  • Yahoo Finance Video

    Influencers with Andy Serwer: David Ricks

    In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

  • Yahoo Finance Video

    By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEO

    Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.

  • Financial Times

    Brussels’ Teva probe reveals dark side of patent protections

    In March, the European Commission said it would probe whether an Israeli drugmaker used patents to stave off competition. In its investigation, Brussels will assess whether Teva “abusively blocked or delayed” market competition for Copaxone, its blockbuster multiple sclerosis drug, by strategically filing and withdrawing “divisional” patents. As such, they potentially enable drug creators to prolong the market exclusivity of products beyond the expiry of their original patents by filing new claims, which in effect extend their monopoly and block generic manufacturers.